Psychedelic research and access in
South Carolina
South Carolina remains a prohibition state for classical psychedelics. State sources reviewed here show psilocybin and psilocin sitting within the Schedule I framework, and there is no verified state-regulated psilocybin, MDMA or natural-medicine access pathway.
Key Insights
- 1
South Carolina remains a prohibition state for classical psychedelics with no verified reform pathway.
- 2
The main 2026 legislative development found was restrictive, not permissive: Bill 1039 would add substituted tryptamines to Schedule I.
- 3
Real-world patient access is ketamine/esketamine through ordinary psychiatric care, with MUSC the clearest verified hub.
- 4
The ecosystem is centred on MUSC rather than on a broad commercial or civic psychedelic scene.
- 5
South Carolina should not be described as an emerging implementation state for psychedelic services.
Research Snapshot
Deep reportBlossom currently tracks 19 psychedelic clinical trials with verified sites in South Carolina, including 2 active studies.
- Active trials
- 2
- Total trials
- 19
- Stakeholders
- 1
- Events
- 0
Verified state-linked study sites
Linked trial records
1 physical, 0 jurisdiction-linked
Linked state-level events
Top Compounds
- MDMA(10)
- Ketamine(5)
- Esketamine(3)
- LSD(1)
Top Study Topics
- PTSD(9)
- Major Depressive Disorder (MDD)(3)
- Treatment-Resistant Depression (TRD)(2)
- Anxiety Disorders(1)
- Healthy Volunteers(1)
Access and Reimbursement
Ketamine/esketamine access; no state-regulated classical psychedelic pathwayPractical access in South Carolina is centred on ordinary ketamine and esketamine care. MUSC has publicly described its ketamine clinic and the use of ketamine and esketamine for difficult-to-treat depression, and it described the 2019 FDA-approved esketamine route as requiring supervised treatment. There is no verified South Carolina-authorised route for psilocybin services or MDMA-assisted therapy outside research.
Research signal
AvailableThe strongest verified node is MUSC. MUSC’s psychiatry department has publicly highlighted ketamine treatment capacity and broader behavioural-health research strength, and MUSC published a 2022 profile of a psychiatrist there who is studying psychedelics conceptually and clinically.
Ketamine / esketamine
AvailablePractical access in South Carolina is centred on ordinary ketamine and esketamine care. MUSC has publicly described its ketamine clinic and the use of ketamine and esketamine for difficult-to-treat depression, and it described the 2019 FDA-approved esketamine route as requiring supervised treatment.
No state service model
Not AvailableNo state-regulated psilocybin, MDMA or natural-medicine service model is verified for South Carolina.
Classical psychedelics
Not AvailableSouth Carolina’s policy posture is straightforwardly conservative. The state materials reviewed do not show decriminalisation, task-force, supervised-use or service-centre legislation.
Reimbursement / payment
LimitedCoverage appears plan-specific, with off-label ketamine generally facing more reimbursement friction than REMS-governed esketamine.
Policy and Access Timeline
State-level bills, laws, pilots, agency actions and reimbursement signals that shape real-world access.
1 Mar 2026
ActiveAgency GuidanceSouth Carolina Bill 1039 filed to add substituted tryptamines to Schedule I
South Carolina Bill 1039 filed to add substituted tryptamines to Schedule I.
South CarolinaBill 1039→1 Mar 2019
ActivePolicy UpdateMUSC highlights the arrival of FDA-approved esketamine treatment
MUSC highlights the arrival of FDA-approved esketamine treatment.
South CarolinaMUSC ketamine clinic article→
Regulatory Status
South Carolina remains a prohibition state for classical psychedelics. State sources reviewed here show psilocybin and psilocin sitting within the Schedule I framework, and there is no verified state-regulated psilocybin, MDMA or natural-medicine access pathway. The main 2026 legislative signal located in primary state materials was not a liberalisation bill, but Bill 1039, which would amend Section 44-53-190 to add substituted tryptamines to Schedule I. For professional readers, that is the opposite of a reform signal: it suggests continued maintenance and expansion of prohibition rather than movement towards supervised therapeutic access.
Medical Access Summary
Practical access in South Carolina is centred on ordinary ketamine and esketamine care. MUSC has publicly described its ketamine clinic and the use of ketamine and esketamine for difficult-to-treat depression, and it described the 2019 FDA-approved esketamine route as requiring supervised treatment.###
There is no verified South Carolina-authorised route for psilocybin services or MDMA-assisted therapy outside research. As elsewhere, off-label ketamine should be treated as standard medical care within existing professional licensure, not as evidence of psychedelic policy reform.###
Local Research Map
Verified Blossom records with coordinates in South Carolina, including trial sites, physical stakeholders and events.
Policy and Access Context
South Carolina’s policy posture is straightforwardly conservative. The state materials reviewed do not show decriminalisation, task-force, supervised-use or service-centre legislation. Instead, the most visible current bill tightens the Schedule I framework by adding substituted tryptamines.###
That leaves access dependent on clinical practice rather than legislative innovation. Investors, journalists and conference planners should therefore read South Carolina as a conventional medical-services state with academic ketamine capability, not as an emerging psychedelic-policy jurisdiction.###
Research Focus
The strongest verified node is MUSC. MUSC’s psychiatry department has publicly highlighted ketamine treatment capacity and broader behavioural-health research strength, and MUSC published a 2022 profile of a psychiatrist there who is studying psychedelics conceptually and clinically.###
What is missing in the reviewed materials is evidence of a major in-state classical psychedelic trial portfolio comparable with Texas or larger coastal research centres. South Carolina should therefore be positioned as ketamine-capable and academically interested, but not as a confirmed classical-psychedelic trial hub on current evidence.###
Implementation Context
Because there is no progressive psychedelic statute to implement, South Carolina has no verified facilitator regime, service-centre licensing system or dedicated psychedelic agency track. The meaningful implementation question is simply how existing health systems deliver ketamine/esketamine inside standard medical regulation.###
If Bill 1039 or related scheduling maintenance moves forward, implementation is a standard controlled-substances exercise rather than a health-service build-out. That keeps South Carolina far from the implementation complexity seen in Oregon-style service models.###
Ecosystem Context
MUSC dominates the verified ecosystem picture. It appears as the clearest physical hub for treatment-resistant-depression innovation involving ketamine and esketamine, and its psychiatry department has emphasised both treatment and research capacity.###
Beyond MUSC, this review did not surface a comparably visible in-state network of psychedelic non-profits, conferences or public task forces. South Carolina therefore looks concentrated rather than distributed: one strong academic-health-system node, limited policy momentum, and little evidence of a statewide reform ecosystem.###
Key Milestones
Future Outlook
Over the next 12 to 24 months, South Carolina is more likely to deepen institutional ketamine/esketamine care than to create a classical psychedelic framework. The verified policy signal points towards schedule maintenance, not towards decriminalisation or supervised psilocybin services.###
The most plausible upside for the state is academic and clinical rather than statutory: additional psychiatric research or service expansion through MUSC. Unless new bills emerge, patient access for classical psychedelics is unlikely to change materially.###
Sources and Verification
Last updated 18 May 2026. Source links are drawn from citation annotations in the subnational report.
State-Linked Stakeholders
Organisations with verified physical locations or jurisdiction-level coverage in South Carolina.
Clinical Trials
Trial records with verified sites in South Carolina.